This image provided by Bristol Myers Squibb in October 2024 shows production of the company's drug Cobenfy, which the U.S. Food and Drug Administration approved for the treatment of schizophrenia in September 2024. (Bristol Myers Squibb via AP)

News, Photo and Web Search

Other Photos

Previous Photo

Next Photo